Publication | Open Access
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy
113
Citations
55
References
2020
Year
EngineeringPatient SelectionPharmacotherapyDifferent Primary OriginRadiation MedicineOncologyNanets/snmmi Consensus StatementTheranosticsRadiopharmaceutical TherapyNeuroendocrine TumorsRadiation OncologyNuclear MedicineCancer ResearchRadiologyRadiation TherapyRadiological SciencesRadionuclide TherapyAppropriate UsePharmacologyEndocrine-related CancerNeuroendocrine DisorderMedicine
With the growing use of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), there are many unanswered questions regarding patient selection. In this document, we review the literature on the use of 177Lu-DOTATATE in neuroendocrine tumors (NETs) of different primary origin, discuss issues of
| Year | Citations | |
|---|---|---|
Page 1
Page 1